COMPOSITION:
TRIBLEND VG 1
Each uncoated bilayer tablet contains-
Glimepiride………………………… 1 mg
Voglibose………………………. 0.2 mg
Metformin (Sustain Release)… 500 mg
TRIBLEND VG 2
Each uncoated bilayer tablet contains-
Glimepiride………………………… 2 mg
Voglibose………………………. 0.2 mg
Metformin (Sustain Release)… 500 mg
DESCRIPTION:
TRIBLEND VG contains three oral anti-hyperglycemic drugs Glimepiride, Voglibose, and Metformin hydrochloride sustained release used in the management of type 2 diabetes (NIDDM). The primary mechanism of action of Glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels. Metformin hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Hence, the combination of Glimepiride; Voglibose and Metformin sustained release complements each other and provides better glycaemic control in the management of Type 2 diabetes and probably in the prevention of its associated macrovascular and microvascular complications.
INDICATIONS:
TRIBLEND VG tablets, used as a once per day, are indicated as an adjunct to diet and exercise, to lower blood glucose. It is indicated as second-line therapy when diet, exercise, and single agents or dual therapy do not result in adequate glycaemic control in patients with type 2 diabetes.
DOSAGE:
The dosage and duration of Metformin + Glimepiride + Voglibose therapy should be as prescribed by a physician.
PRECAUTIONS:
Metformin + Glimepiride + Voglibose are contraindicated in patients with cardiovascular collapse, hepatic insufficiency, renal failure, thyroid dysfunctions, acute heart failure with unstable angina, stenosis, renal impairment, diabetic ketoacidosis, SIADH, hepatic cirrhosis and iatrogenic hypersensitivity